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A B S T R A C T
Background: Medication administration errors may contribute to patient mortality, thus additional under-
standing of such incidents is required.
Objectives: To analyse medication administration errors reported in acute care resulting in death, to identify the
drugs concerned, and to describe medication administration error characteristics (location of error, error type,
patient's age) by drug group.
Methods: Medication administration errors reported in acute care in 2007 ̶ 2016 (n=517,384) were obtained
from the National Reporting and Learning System for England and Wales. Incidents reported as resulting in death
(n=229) were analysed. Drugs were classiﬁed by two researchers using the British National Formulary. Drug
categories were described by medication administration errors' year, location, patient age, and error category
based on the incidents’ original classiﬁcation.
Results: Errors were most often reported on wards (66.4%, n=152), and in patients aged over 75 years (41.5%,
n= 95). The most common error category was omitted medicine or ingredient (31.4%, n=72); most common
drug groups were cardiovascular (20.1%, n= 46) and nervous system (10.0%, n= 23). Most errors in patients
under 12 years concerned drugs to treat infection; cardiovascular drugs were most common among other age
groups.
Conclusions: In order to prevent these most serious of medication administration errors, interventions should
focus on avoiding dose omissions, and administration of drugs for patients over 75 years old, as well as safe
administration of parenteral anticoagulants and antibacterial drugs.
Introduction
In 2017, The World Health Organisation (WHO) launched a third
global patient safety challenge “Medication Without Harm”, aimed at
improving medication safety, on the basis that medication errors are a
leading cause of injury and avoidable harm in health care systems
globally generating costs that has been estimated at 42 billion USD
annually.1 In February 2018, the report of the prevalence and burden of
medication errors in England was published in response to the WHO
challenge, estimating that 237 million medication errors at all stage of
medication process occur in England per annum.2
The United States National Coordinating Council for Medication
Error Reporting and Prevention³ deﬁnes medication error as “any pre-
ventable event that may cause or lead to inappropriate medication use
or patient harm while the medication is in the control of the health care
professional, patient, or consumer”. The medication administration
stage of the medication process is known to be prone to errors. Half or
more of all medication incidents are medication administration errors
(MAEs).2,4,5 MAEs can be deﬁned as “a deviation from the prescriber's
medication order as written on the patient's chart, manufacturers' pre-
paration/administration instructions, or relevant institutional po-
licies”.6 Direct observations of the inpatient medication process pro-
duce the most rigorous data on the prevalence of medication errors, and
suggest that MAEs occur in 5% of non-intravenous and 35% of
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intravenous doses⁷ or up to 20% of all doses given.8,9 Fortunately, the
majority of MAEs do not result in harm,2,10 but some are serious or even
fatal. An adverse drug event (ADE) is deﬁned as “an injury resulting
from medical intervention related to a drug".11
Medication errors as well as ADEs during hospitalization are more
likely in the presence of co-morbidity and polypharmacy,2,12 and
among older people.2,13 Some drugs are more likely to cause signiﬁcant
patient harm when used in error. These are listed as high-alert medi-
cations by the US Institute for Safe Medication Practices (ISMP).14 In
acute care settings, these drug classes include anaesthetics, anti-ar-
rhythmics, anti-thrombotics, chemotherapeutics, dialysis solutions,
epidural or intrathecal medications, insulin, narcotics/opioids, and
parenteral nutrition.14 The UK's high risk drug list includes adminis-
tration of methotrexate, diamorphine and morphine injections, low
molecular weight heparins, anticoagulants, insulin, lithium, midazolam
injection, opioids, injectable medicines, and liquid medicines as well as
omitted doses.15 Additionally, a systematic review revealed that 47% of
all serious medication errors were caused by seven drugs/drug classes.
Those were methotrexate, warfarin, nonsteroidal anti-inﬂammatory
drugs (NSAIDS), digoxin, opioids, acetylic salicylic acid, and beta-
blockers.16
Analysis of reported medication errors have traditionally included
all medication incidents, whether or not they result in harm.4,5 By
focussing on the most serious MAEs, the aim was to speciﬁcally study
the characteristics of MAEs reported as resulting in patient death. This
study's objectives were 1) to analyse medication administration errors
reported in acute care resulting in death, 2) to identify the drugs con-
cerned, 3) to describe MAE characteristics by drug group, and 4) to
identify potential areas for intervention.
Methods
Design & setting
This was a retrospective study of MAEs reported to the National
Reporting & Learning System (NRLS) for England and Wales. The NRLS
collects national data on all patient safety incidents that are voluntarily
and anonymously reported by staﬀ employed in the National Health
Services (NHS) and other health care organisations. Incidents (in-
cluding near misses and incidents causing harm) can also be reported
directly to the NRLS. Data reported for incidents include both catego-
rical data (e.g. type, severity of incident) and a free text description of
what happened.
The original classiﬁcation of the NRLS incidents was used. Based on
this classiﬁcation, location of error included: ward, intensive care unit,
operating theatre, recovery room, anaesthetic room, therapy depart-
ment, pharmacy, mortuary, hospital buildings, other, or the informa-
tion was missing. Types of errors were: omitted medicine/ingredient,
wrong/unclear dose or strength, wrong drug/medicine, wrong fre-
quency, wrong quantity, wrong route, adverse drug reaction (when
used as intended), patient allergic to treatment, contra-indication to the
use of the medicine in relation to drugs or conditions, mismatching
between patient and medicine, wrong storage, wrong method of pre-
paration/supply, wrong/omitted verbal patient directions, wrong/
omitted/passed expiry date, other, or unknown.
Data acquisition
A data sharing agreement was signed after applying and receiving
acceptance from NRLS for data access. NRLS extracted the data (med-
ication administration errors reported to the NRLS between 1 January
2007 and 31 December 2016) in December 2017. Inclusion criteria
were that the incident was documented as involving: 1) medication, 2)
administration/supply of a medicine from a clinical area, and 3) acute
NHS trust (either a specialist or non-specialist organisation). Of all in-
cidents (n=517,384), 94.3% concerned an acute non-specialist Trust,
and only 5.7% acute specialist Trust. The total number of incidents
extracted was 517,384. Of these, only MAEs reported as resulting in
death caused by a patient safety incident (n=229, 0.04%) were ana-
lysed. Only the categorical data ﬁelds within the NRLS data were ac-
quired.
Data analysis
Descriptive statistics of the data (n=229 MAEs reported as re-
sulting in death) were calculated using IBM SPSS (version 23.0).
Characteristics of the data were described using frequencies and per-
centages, and relationships amongst factors explored via cross-tabula-
tion. Reports including the name of the drug were classiﬁed using the
British National Formulary (BNF) classiﬁcation.17 The BNF classiﬁca-
tion's main groups are divided under the following sections: 1. Gastro-
intestinal system, 2. Cardiovascular system, 3. Respiratory system, 4.
Nervous system, 5. Infection, 6. Endocrine system, 7. Genito-urinary
system, 8. Malignant disease, 9. Blood and nutrition, 10. Musculoske-
letal system, 11. Eye, 12. Ear, nose, and oropharynx, 13. Skin, 14.
Vaccines, 15. Anaesthesia, and 16. Emergency treatment of poisoning.
MH classiﬁed the drugs into BNF groups which were then veriﬁed by
BDF. Drug categories were cross-tabulated by MAEs' year, location,
patients' age, and error category. The age bands used within the NRLS
were amalgamated into six broader groups: 1) under 12 years, 2) 12–17
years, 3) 18–25 years, 4) 26–55 years, 5) 56–75 years, and 6) over 75
years.
Ethics
King's College London ethics committee approved the study (LRS-
17/18–5150). The data did not include any personal or organisational
identiﬁers, thus anonymity of the reporters, patients, other involved
persons, and organisations could be guaranteed.
Results
Characteristics of MAEs resulting in death
MAEs resulting in death (n= 229) occurred most often in 2008
(n= 28, 12.2% of all MAEs reported as causing death) and 2016
(n= 28, 12.2%), and less often 2012 (n=13, 5.7%). Overall 66.4% of
MAEs were reported as occurring on non-critical care wards, and 41.5%
(n= 95) occurred amongst patients aged over 75 years. The most
common error category was omitted medicine or ingredient (n= 72,
31.4%) (Table 1.).
Drugs related to MAEs
The name of the related drug was mentioned in 58.1% (n= 133) of
all MAEs. The most common group of drugs in MAEs reported as re-
sulting in death were cardiovascular drugs (20.1%, n=46). Of these 26
involved parenteral anticoagulants, six oral anticoagulants, and six
sympathomimetics. The second most common were drugs of the central
nervous system (10.0%, n= 23). Of those, analgesics (n=10) were
most common. Other common drug groups were antibacterials
(n= 20), cytotoxic drugs (n=8), and insulin (n=7) (Table 2.). More
Abbreviations
ADE adverse drug event
BNF British National Formulary
ISMP Institute for Safe Medication Practices
MAE medication administration error
NHS National Health Service
NRLS National Reporting & Learning System
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speciﬁc information by name of drugs concerned (as written in the
reports) is presented in Table 3.
MAE characteristics by drug groups
MAEs reported as resulting in death in general ward areas were
most often reported for cardiovascular drugs (34 cases of 152 incidents
at ward) followed by nervous systems drugs (19 of 152). MAEs occur-
ring in intensive care units most commonly concerned drugs used in
blood and nutrition (4 of 18 incidents in intensive care units) and in-
fection (3 of 18). Most MAEs in patients under 12 years were drugs to
treat infection (3 of 10 incidents in patients under 12 years) whereas for
patient's aged 26–55 years cardiovascular drugs (6 of 29 incidents in
patients aged 26–55 years) were the most common. Cardiovascular
drugs (9 of 58 of incidents in patients aged 56–75) or drugs to treat
infection (10 of 58) featured most often for patients aged 56–75, and
cardiovascular drugs (23 of 95 incidents in patients aged over 75 years)
and nervous system drugs (11 of 95) for patients aged over 75. (Online
appendix.)
The most common error categories for cardiovascular drugs were
omitted medicine/ingredients (18 of 46 incidents with cardiovascular
drugs), followed by wrong/unclear dose or strength (6 of 46). For
nervous system drugs the most commonly reported errors were wrong/
unclear dose or strength (4 of 23 incidents with nervous system drugs),
wrong quantity (3 of 23), and wrong drug/medicine (3 of 23). For drugs
to treat infection the most commonly reported errors were omitted
medicine/ingredient (5 of 21 incidents with drugs to treat infection),
adverse drug reaction (4 of 21), and patient allergic to treatment (4 of
21). (Online appendix.)
Discussion
In this study, MAEs most commonly reported as causing mortality in
acute cate Trusts over the 10-year period 2007 to 2016 were omissions
of drugs. They occurred more often on hospital wards than other lo-
cations and amongst patients aged over 75 years. The drugs most
commonly involved were parenteral anticoagulants followed by
Table 1
Characteristics of medication administration incidents resulting in death
(n=229).
Variable No. %
Year
- 2007 23 10.0
- 2008 28 12.2
- 2009 19 8.3
- 2010 22 9.6
- 2011 26 11.4
- 2012 13 5.7
- 2013 25 10.9
- 2014 24 10.5
- 2015 21 9.2
- 2016 28 12.2
Location
- Ward 152 66.4
- Intensive care unit/high dependency unit 18 7.9
- Operating theatre 10 4.4
- Other 4 1.7
- Recovery room 2 0.9
- Hospital buildings (inside) 2 0.9
- Therapy department 2 0.9
- Pharmacy 1 0.4
- Anaesthetic room 1 0.4
- Mortuary 1 0.4
- Missing information 36 15.7
Patient's age
- under 12 10 4.4
- 12-17 0 0.0
- 18-25 2 0.9
- 26-55 29 12.7
- 56-75 58 25.3
- over 75 95 41.5
- Missing 35 15.2
Medication error category
- Omitted medicine/ingredient 72 31.4
- Other 37 16.2
- Wrong/unclear dose or strength 24 10.5
- Adverse drug reaction (when used as intended) 21 9.2
- Wrong drug/medicine 16 7.0
- Wrong frequency 13 5.6
- Wrong quantity 13 5.6
- Wrong route 8 3.5
- Patient allergic to treatment 7 3.1
- Contra-indication to the use of the medicine in relation to drugs
or conditions
5 2.2
- Mismatching between patient and medicine 3 1.3
- Unknown 3 1.3
- Wrong storage 2 0.9
- Wrong method of preparation/supply 2 0.9
- Wrong/omitted verbal patient directions 2 0.9
- Wrong/omitted/passed expiry date 1 0.4
Table 2
Classiﬁed drugs related to death causing medication administration incidents
(n= 229).
BNF Drug classes No. %
1. Gastro-intestinal system 0 0.0
2. Cardiovascular system 46 20.1
- 2.2 (n= 1) Diuretics
- 2.3 (n= 2) Anti-Arrhythmic Drugs
- 2.5 (n= 2) Hypertension and Heart Failure
- 2.7 (n= 6) Sympathomimetic
- 2.8 (n= 26) Parenteral Anticoagulants, (n= 6) Oral
Anticoagulants
- 2.10 (n= 1) Stable Angina, Acute/Coronary Synd&Fibrin
- 2.11 (n= 2) Antiﬁbrinolytic Drugs & Haemostatics
3. Respiratory system 2 0.9
- 3.6 (n= 2) Oxygen
4. Nervous system 23 10.0
- 4.1 (n= 3) Hypnotics And Anxiolytics
- .2 (n=1) Drugs Used In Psychoses & Rel.Disorders
- 4.3 (n= 1) Antidepressant Drugs
- 4.6 (n= 1) Drugs Used In Nausea And Vertigo
- 4.7 (n= 10) Analgesics
- 4.8 (n= 6) Antiepileptic Drugs
- 4.9 (n= 1) Drugs Used In Parkinsonism/Related Disorders
5. Infection 21 9.2
- 5.1 (n= 20) Antibacterial Drugs
- 5.3 (n= 1) Antiviral Drugs
6. Endocrine system 8 3.5
- 6.1.1 (n=7) Insulin
- 6.3 (n= 1) Corticosteroids (Endocrine)
7. Genito-urinary system 0 0.0
8. Malignant disease 9 3.9
- 8.1 (n= 8) Cytotoxic Drugs
- 8.2 (n= 1) Drugs Aﬀecting The Immune Response
9. Blood and nutrition 11 4.8
- 9.1 (n = 1) Anaemias + Other Blood Disorders
- 9.2 (n= 4) Fluids And Electrolytes
- 9.3 (n= 2) Intravenous Nutrition
- 9.5 (n= 4) Minerals
10. Musculoskeletal system 1 0.4
- 10.2 (n= 1) Drugs Used In Neuromuscular Disorders
11. Eye 1 0.4
- 11.8 (n= 1) Miscellaneous Ophthalmic Preparations
12. Ear, nose, and oropharynx 0 0.0
13. Skin 3 1.3
- 13.11 (n=3) Skin Cleansers, Antiseptics & Desloughing
14. Vaccines 0 0.0
15. Anaesthesia 1 0.4
- 15.1 (n= 1) General Anaesthesia
16. Emergency treatment of poisoning 2 0.9
Multiple 2 0.9
Other 3 1.3
Missing 96 41.9
Total 229 100
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antibacterial drugs. Interventions to reduce MAEs, should therefore
focus on those areas.
Almost one third of MAEs were related to omissions of drug doses. A
previous study analysing all medication errors reported to the NRLS
between 2005 and 2010 also found that omissions were the most
commonly reported type, accounting for around 15% of incidents,4
which is much lower than in the present study. In addition, a previous
systematic review using observational evidence demonstrated that
omission errors are the most common MAE type internationally.18 More
attention is needed on omissions since the consequences can be serious.
The risks of delay or omission of drugs have been categorised by the
English National Patient safety Agency (NPSA),19 which suggests that
omission of anticoagulants, insulins, and cytotoxic agents, as identiﬁed
in this study, can cause signiﬁcant or catastrophic long-term patient
impact. Reasons for medication omissions are manifold, such as staﬀ
shortages and delays in medication dispensing,20 patients' inability to
take the medicine, or medication unavailability.21 More active solutions
for problems related to medication omissions should be implemented
with the development of technology, improving work processes, ﬂow of
information, veriﬁcation systems and availability of drugs. Still, it is
challenging to recommend any speciﬁc interventions, as a previous
systematic review and meta-analysis demonstrated that interventions
developed to decrease MAEs, including nurse training and education,
automated delivery systems and barcode-assisted medication adminis-
tration systems, did not ﬁnd clear eﬀect of the interventions.22
Cardiovascular drugs, particularly parenteral anticoagulants, were
the most common drug group involved in MAEs reported as resulting in
death. Many of those were omitted or administered in the wrong dose,
strength, frequency, or quantity. Cardiovascular drugs were associated
with the highest median proportion of preventable adverse drug reac-
tions (PADR) also in a previous review of systematic reviews of in-
patients’ PADRs.23 Those were also found to be the most frequent types
of drugs involved in preventable ADEs,24 and commonly related to
observed MAEs.18 Similarly, heparin and low molecular weight heparin
were amongst the most common drugs reported as causing death in
other previous studies,⁴,⁵ demonstrating that the consequences of an
error are more devastating for patients receiving these types of drugs as
there is only a narrow diﬀerence between an eﬀective and a toxic dose.5
In addition, omission of such drugs may have a signiﬁcant or cata-
strophic long-term impact 19 and the risk of ADEs has been found to
increase especially for inpatients with coronary disease and using re-
lated drugs.12 Thus, eﬀorts to avoid dose omissions should focus on
these patients.
Antibacterial drugs were also a common group of drugs identiﬁed in
the present study. Most MAEs related to these drugs were omissions,
adverse drug reactions, and administration to patients with a docu-
mented allergy. These drugs have been previously found to be related to
medication errors causing death,⁴ but are not amongst ISMP's list of
high-alert medications.14 The data in the present study show that pa-
tients' allergies and other adverse reactions of drugs may not be veriﬁed
Table 3
Names of the drugs related to death causing incidents (as written in reports). Online appendix. Medication administration incidents (n= 229) characteristics by drug
groups.
BNF code Drug names (as written in incident reports)
2.Cardiovascular system
2.2 Diuretics bumetanide
2.3 Anti-Arrhythmic Drugs Digoxin [digitalis], amiodarone
2.5 Hypertension and Heart Failure doxazosin and ramipril, verapamil
2.7 Sympathomimetic noradrenaline x6, adrenaline x2, isoprenaline, metaraminol
2.8 Parenteral Anticoagulants &
Oral Anticoagulants
enoxaparin x 7, Clexane [enoxaparin] x 6, heparin x 6, tinazaparin x 3, Fragmin [dalteparin sodium] x 4, warfarin x 3,
rivaroxiban x 2, apixaban
2.10 Stable Angina, Acute/Crnry Synd&Fibrin alteplase
2.11 Antiﬁbrinolytic Drugs & Haemostatics factor VIII, vitamin K
3. Respiratory system
3.6 Oxygen oxygen x 2
4. Nervous system
4.1 Hypnotics And Anxiolytics midazolam x 2, lorazepam
4.2 Drugs Used In Psychoses & Rel.Disorders haloperidol
4.3 Antidepressant Drugs mirtazapine
4.6 Drugs in Nausea And Vertigo prochlorperazine/cyclizine,
4.7 Analgesics aspirin, oxycodene x 3, fentanyl, remifentanil, morphine x 2, diamorphine, buprenorphine
4.8 Antiepileptic Drugs phenytoin x 4, phenobarbital, thiopentone
4.9 Park'ism/Related Disorders co-careldopa
5. Infection
5.1 Antibacterial Drugs co-amoxiclav x 4, gentamicin x 3, Augmentin [amoxicillin and clavulanate] x 3, Tazocin [piperacillin sodium/tazobactam
sodium] x 2, cefuroxime, ﬂucloxicillin x2, daptomycin, benzylpenicillin, rifampicin, trimethoprim, levoﬂoxacin, linezolid
5.3 Antiviral Drugs abacavir
6. Endocrine system
6.1.1 Insulin insulin x 7
6.3 Corticosteroids (Endocrine) hydrocortisone
8. Malignant disease
8.1 Cytotoxic Drugs chemotherapy x 2, cyclophosphamide x 2, eribulin, vinorelbine, ifosfamide, bleomycin
8.2 Immune Response Drugs alemtuzumab
9. Blood and nutrition
9.1 Anaemias + Blood Disorders iron dextran
9.2 Fluids And Electrolytes potassium chloride x2, 0.9% normal saline 1000ml, sando K
9.3 Intravenous Nutrition glucose, Vamin [amino acids]
9.5 Minerals magnesium x2, calcium chloride x 2
10. Musculoskeletal system
10.2 Drugs In Neuromusc. Disord. pyridostigmine
11. Eye/Miscellaneous Ophthalmic Preparations ﬂuorescein
13. Skin
13.11 Clean., Antisep. & Desloughing chlorhexidine, potassium permanganate
15. Anaesthesia
15.1 General Anaesthesia atropine
16. Emerg. treatment of poisoning ﬂumazenil, protamine sulphate
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as carefully as required. Other common drugs related to patients' deaths
were opioids, insulins, and cytotoxic drugs, all in ISMP's list of high-
alert medications.14 The most common error types for nervous systems
drugs (including opioids) were wrong or unclear dose or strength,
wrong drug, or wrong quantity. Further research is needed to under-
stand the reasons for these error types.
Each death caused by medication error is one death too many. There
should also be some focus on rare and unusual MAEs. For example two
MAEs resulting in death were caused by the administration of po-
tassium permanganate (orally instead of topically). An NPSA Patient
Safety Alert produced in 2014 was based on death caused by a patient
ingesting potassium permanganate.25 One incident in our data occurred
before this alert and another afterwards, in 2016. More knowledge and
competence in handling drugs and administration of drugs should be
provided to all health professionals, especially nurses, as they are
usually the ﬁnal step in the medication use process. Educating patients
about the medications they are receiving may help to reduce MAEs.
Strengths and limitations
This study was of a suﬃcient size to be able to identify rare MAEs
that result in death. Drugs were classiﬁed into BNF category by two
researchers, which supports reliability and validity. It is known that
reported incidents do not represent all those that occur, and it is as-
sumed that self-reporting systems (such as the NRLS) detect only a very
small proportion of all medication incidents.2 The incident reporting
system has further possible weaknesses in that reporters may evaluate
the consequences of incidents incorrectly such that some of the MAEs
reported as resulting in death incidents may allude to possible rather
than actual consequences. It was only possible to identify the name of
the drug for 56% of all reports and only the categorical ﬁelds from the
NRLS data were used in this analysis. In addition, the original classiﬁ-
cation of NRLS incidents was used, and it is thus impossible to evaluate
what error types are hidden under the ‘other’ category. A further issue is
whether an ‘adverse drug reaction’ may be an MAE when medication is
administered for the ﬁrst time to the patient, but descriptions of re-
ported incidents did not include enough information to allow re-clas-
siﬁcation. The free text descriptions could have provided a more de-
tailed understanding of each incidents and further information about
the drugs involved.
Conclusion
In order to prevent the most serious MAEs, additional studies and
interventions should focus on dose omissions and administration of
drugs to patients over 75 years old, as well as safe administration of
parenteral anticoagulants and antibacterial drugs. Checking patient
allergies and undertaking required veriﬁcation procedures before
medication administration, as well as additional education for safe
handling and administration of drugs should be mandatory. Additional
studies using observational research methods are important for ex-
ploring further the dynamics of serious MAEs.
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